

Part VI: Summary of the risk management plan

Summary of risk management plan for <Product name> 2g/0.25g, 4g/0.5g powder for solution for infusion (Piperacillin/Tazobactam)

This is a summary of the risk management plan (RMP) for <Product Name>. The RMP details important risks of <Product Name>, how these risks can be minimised, and how more information will be obtained about <Product Name>'s risks and uncertainties (missing information).

<Product Name>'s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how [<Product Name> should be used.

Important new concerns or changes to the current ones will be included in updates of <Product Name>'s RMP.

I. The medicine and what it is used for

<Product name> is indicated for the treatment of the following infections in adults and children over 2 years of age:

Adults and adolescents

- Severe pneumonia including hospital-acquired and ventilator-associated pneumonia
- Complicated urinary tract infections (including pyelonephritis)
- Complicated intra-abdominal infections
- Complicated skin and soft tissue infections (including diabetic foot infections)

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

<Product name> may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection.

Children 2 to 12 years of age

- Complicated intra-abdominal infections

<Product name> may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection.

Consideration should be given to official guidance on the appropriate use of antibacterial agents. (see SmPC for the full indication). It contains piperacillin and tazobactam as the active substances, and it is given by intravenous infusion.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of <Product Name>, together with measures to minimise such risks and the proposed studies for learning more about <Product Name>'s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of <Product Name> are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of <Product Name>. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• None
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of <Product Name>.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for <Product Name>.